New lung Drug's safety check: how does it mix with existing meds?
NCT ID NCT07229716
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial is testing a new drug called HRS-9813 in 20 healthy volunteers to see how it interacts with two standard treatments for pulmonary fibrosis (lung scarring): pirfenidone and nintedanib. The goal is to measure drug levels in the blood and check for side effects. This study does not treat the disease but provides important safety and dosing information for future research.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HRS-9813, pirfenidone, nintedanib
What this could lead to
If successful, this could help determine safe dosing when HRS-9813 is combined with existing pulmonary fibrosis treatments.
What could go wrong
This is an early Phase 1 study in healthy people, not patients. It only measures drug levels and safety, not whether the combination works for the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY FIBROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tangdu Hospital, Fourth Military Medical University
RECRUITINGXi’an, Shanxi, 710026, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact